Sub menu

 
 

IMFINZI (AstraZeneca Pty Ltd)

Product name
IMFINZI
Sponsor
AstraZeneca Pty Ltd
Date registered
Evaluation commenced
Decision date
Approval time
238 (255 working days)
Active ingredients
durvalumab
Registration type
EOI
Indication

Locally advanced non-small cell lung cancer (NSCLC)

IMFINZI is indicated for the treatment of patients with locally advanced, unresectable NSCLC whose disease has not progressed following platinum-based chemoradiation therapy.

Small cell lung cancer (SCLC)

IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).

Biliary tract cancer (BTC)

IMFINZI in combination with gemcitabine and cisplatin is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer (BTC).

Hepatocellular carcinoma (HCC)

IMFINZI in combination with tremelimumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) who have not received prior treatment with a PD-1/PD-L1 inhibitor.

Help us improve the Therapeutic Goods Administration site